Clinical trial Recruiting at 15 sites Phase 2 Interventional Ages 64 and up

Intra-Articular Allocetra for Knee Osteoarthritis

Official title: A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis

Run by Enlivex Therapeutics Ltd. · NCT07580716 · Data updated 2026-11-12

This study tests whether injecting Allocetra into the knee can help people with moderate-to-severe knee osteoarthritis compare to a placebo.

More Knee Osteoarthritis trials

Quick facts

PhasePhase 2
Study typeInterventional
Ages64 Years and up
SexAll
Enrollment182 (estimated)
SponsorEnlivex Therapeutics Ltd.
Industry-sponsored
Locations17 sites (Longwood, Florida and 16 other locations)
StatusRecruiting
StartedMay 1, 2026
Main results expectedFebruary 2027
Study endsApril 2028
Registry record updatedOctober 13, 2026
Trial IDNCT07580716 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 64 and older with radiographic KL grade 2–3 knee OA who have not adequately responded to at least two OA therapies.

Probably not a fit

Patients with lower limb OA not meeting KL criteria or who have contraindications to intra-articular injections may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase IIb, multicenter, randomized, double-blind study compares three ultrasound-guided intra-articular Allocetra injections to placebo in adults aged 64 and older with radiographically confirmed primary knee OA who have not adequately responded to at least two OA therapies. Participants receive injections on Days 0, 14, and 28 and are followed for 12 months to assess pain and function. Allocetra consists of modified allogeneic peripheral blood mononuclear cells designed to promote cartilage-friendly inflammation resolution. The trial seeks to determine if Allocetra can reduce knee pain and improve function compared with placebo. Enrollment occurs at selected sites in Florida and Louisiana.

Why it matters

Potential benefit: If successful, Allocetra could reduce knee pain and improve joint function for people with knee OA.

How similar studies have gone: Previous cell-based approaches for OA have shown mixed results; this trial builds on a growing interest in immunomodulatory therapies for joint inflammation.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Participants must meet all of the inclusion criteria listed below to be eligible for the study:

1. Age 64 years or above.
2. Diagnosis of primary femorotibial knee OA.
3. Radiographic evidence of knee OA defined as Kellgren-Lawrence (KL) grade 2 or 3 in the index knee.
4. Participants who are intolerant to, or have failed to adequately respond to at least 2 OA therapies.
5. Index knee pain assessed during the screening period and following wash-out of pain medications.
6. Willingness to abstain from prohibited medications/treatments during the trial.
7. Women who are postmenopausal (≥12 months natural amenorrhea without alternative cause) or surgically sterilized (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).
8. Male participants with partners of childbearing potential, who are not surgically sterile (vasectomy) for at least 6 months prior to randomization, must use condoms with spermicide in addition to their partner's contraception from randomization and for 90 days after last dose.

Exclusion Criteria:

Participants will be excluded from the study if they meet any of the following criteria:

1. Severe or end-stage osteoarthritis of the index knee.
2. Clinically significant structural abnormalities or instability of the index knee.
3. Recent major injury, surgical procedure, or intra-articular treatment in the index knee.
4. Any known history of infection or tumor of the index knee, or active infection at the intended injection site.
5. Any known history of inflammatory arthropathy or crystal-deposition disease.
6. Any severe systemic cartilage, bone, or musculoskeletal disorder that may interfere with study outcomes.
7. Clinically significant widespread pain syndromes.
8. Immunosuppressive therapy, clinically significant immunodeficiency, or active infection.
9. Body Mass Index (BMI) \>40 kg/m²
10. Use of medications that may interfere with pain assessment or study outcomes.
11. Known coagulopathy or use of anticoagulant/antiaggregant medication.
12. Significant uncontrolled systemic disease or clinically significant findings on screening laboratory tests or physical examination.

Where it's running

  • Future Medical Research
    Longwood, Florida, United States
    Recruiting
  • South Florida Research Phase I-IV
    Miami, Florida, United States
    Recruiting
  • DelRicht Research @ Touro Medical Center
    New Orleans, Louisiana, United States
    Recruiting
  • Oakland Medical Research
    Troy, Michigan, United States
    Recruiting
  • Sanos Clinic Gandrup
    Gandrup, Denmark
    Recruiting
  • Sanos Clinic Herlev
    Herlev, Denmark
    Recruiting
Show 11 more locations
  • Sanos Clinic Vejle
    Vejle, Denmark
    Recruiting
  • NZOZ Bif-Med. s.c
    Bytom, Poland
    Recruiting
  • Vita Longa Sp. z o.o.
    Katowice, Poland
    Recruiting
  • Medyczne Centrum Hetmańska
    Poznan, Poland
    Recruiting
  • Reumedika sp. z o.o.
    Poznan, Poland
    Recruiting
  • DC-MED Michal Kowalski S.K. Swidnica
    Swidnica, Poland
    Recruiting
  • Etg Justmed
    Warsaw, Poland
    Recruiting
  • Etg Warszawa
    Warsaw, Poland
    Recruiting
  • Migre Polskie Centrum
    Wroclaw, Poland
    Recruiting
  • Centrum Medyczne PLEJADY
    Krakow, Poland
    Not yet recruiting
  • DC-MED Michal Kowalski S.K. Radom
    Radom, Poland
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.